Dr. Dul is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
19229 Mack Ave Ste 24
Grosse Pointe Woods, MI 48236Phone+1 313-884-5522Fax+1 313-884-5521
Summary
- Dr. Carrie Dul is an oncologist in Grosse Pointe Woods, MI and is affiliated with multiple hospitals in the area, including Ascension St. John Hospital, Henry Ford Bi-County Hospital, Henry Ford Macomb Hospitals, Ascension Macomb-Oakland Hospital, Ascension Crittenton Hospital Medical Center, and Beaumont Hospital - Grosse Pointe. She received her medical degree from University of North Carolina at Chapel Hill School of Medicine and has been in practice 18 years. She specializes in breast cancer and hematologic oncology.
Education & Training
Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2002 - 2005- Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 1999 - 2002
University of North Carolina at Chapel Hill School of MedicineClass of 1999
Certifications & Licensure
OR State Medical License 2001 - Present
MI State Medical License 2004 - 2024
IN State Medical License 2003 - 2004- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2014
Clinical Trials
- NBRST: Prospective Neo-adjuvant REGISTRY Trial Start of enrollment: 2011 Jul 01
Publications & Presentations
PubMed
- 58 citationsChemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted b...Pat Whitworth, Peter D. Beitsch, Angela Mislowsky, James Pellicane, Charles Nash
Annals of Surgical Oncology. 2017-03-01 - 31 citationsPertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).Peter D. Beitsch, Pat Whitworth, Paul L. Baron, Michael Rotkis, Angela Mislowsky
Annals of Surgical Oncology. 2017-04-26 - 5 citationsAge-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer.Pat Whitworth, Peter D Beitsch, James V Pellicane, Paul L Baron, Laura A Lee
Annals of Surgical Oncology. 2022-04-04
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
